ClinicalTrials.gg
CompletedNCT06678581Updated Nov 12, 2024

SAD,MAD and Food Effect Study of SAP-001 Tablets in Chinese Subjects

A Phase 1 interventional study of SAP-001 and Placebo in Gout and Hyperuricemia, sponsored by Shanton Pharma Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by Shanton Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Gout with a site in China — 11 open to participants now, 15 under way, 2 of them phase 3. Gout · China.

Enrollment
26th of 44
70 · median 93
Started
2023
with 6 others
Phase 1
16 of 49
4 open now
Registered
30th of 49
by date

Among the 49 studies in Gout with a site in China, this one is the 26th largest by enrollment of the 44 interventional ones that give a count, is one of 7 that started in 2023, is one of 16 in phase 1, and was the 30th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

11 of the 49 studies in Gout with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Gout with a site in China, or all of them as a file.
02

Study summary

To evaluate the pharmacokinetics (PK) profile of single or multiple oral doses of SAP-001 tablets in healthy Chinese subjects and gout patients with hyperuricemia.

To evaluate the safety and tolerability of single oral doses of SAP-001 tablets in healthy Chinese subjects and multiple oral doses of SAP-001 tablets in gout patients with hyperuricemia. To evaluate the pharmacodynamics (PD) profile of single oral doses of SAP-001 tablets in healthy Chinese subjects and multiple oral doses of SAP-001 tablets in gout patients with hyperuricemia.

To evaluate the pharmacokinetics profile of SAP-001 tablets in healthy Chinese subjects under fasted/fed conditions.

03

Conditions studied

  • Gout
  • Hyperuricemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

For SAD and FE study

Inclusion Criteria:

  • Male or female Chinese subjects between the ages of 18 and 55 years (inclusive of the cutoff value, the time of signing the shall prevail) in good health (as determined by medical history, physical examination, 12-lead [heart rate > 50 bpm, PR interval \< 200 ms, and QRS width \< 120 ms], vital sign measurements, and normal or no abnormalities in clinical laboratory evaluations as assessed by the investigator (or designee) at screening and Day -1);
  • between 18 and 28 kg/m2 (including the cutoff value) at screening, not less than 50 kg for men and 45 kg for women;
  • Serum uric acid (sUA) level ≤ 420 μmol/L (7 mg/dL) during the screening period and no history of gout;
  • Males and females of must agree to use at least one medically acceptable form of (see Appendix for specific contraceptive measures) from screening through 3 months after the last dose;
  • The subjects fully understand the purpose, nature, method and possible adverse reactions of the trial, voluntarily acts as a subject, and signs the informed consent form;
  • Able to complete trial per protocol requirements.

Exclusion Criteria:

  • Clinically abnormal diseases or factors, including but not limited to neurological, cardiovascular, hematological, hepatic, renal, gastrointestinal, respiratory, metabolic, endocrine, immunological, skeletal system diseases or other factors, which investigator considered inappropriate for study participation;
  • Subjects with a history of gastrointestinal surgery or resection (subjects who have undergone appendectomy and/or herniorrhaphy may be included in the study);
  • Clinically significant liver function test abnormalities define as (AST) or alanine aminotransferase (ALT) > 1.5 times of the (ULN) or total (TBIL) > ULN at screening or baseline (D-1); or history of clinically significant acute or chronic hepatitis (including infectious, metabolic, , hereditary, ischemic, or other forms), liver cirrhosis, or liver tumor.

    • Significant cardiovascular diseases, including:

      1. Acute decompensated heart failure, including exacerbation of chronic heart failure, manifests as signs and symptoms requiring hospitalization and/or intravenous diuretic therapy [ (NYHA) class III to IV], or hemodynamically significant valvular disease and/or other vascular obstructive lesions within 3 months prior to the screening visit;
      2. Any of the following within 6 months prior to the screening visit:

        • Significant cardiac, cerebral, and/or carotid artery diseases, including but not limited to acute coronary syndrome, myocardial infarction, stroke, and/or , or unsatisfactory recovery or unstable control at screening;
        • Major cardiovascular or percutaneous procedures, including cardiac ablation, coronary revascularization, and carotid angioplasty; cardiovascular disease likely to require surgical or percutaneous intervention during participation in the study or within 6 months of the screening visit;
      3. History of clinically significant cardiac arrhythmia, including but not limited to any of the following:

        • Symptomatic bradycardia and/or symptomatic ventricular arrhythmia within 3 months prior to the screening visit;
        • Second- or third-degree atrioventricular block, sick sinus syndrome, left bundle branch block;
        • > 450 ms for males and > 470 ms for females prior to screening or randomization;
        • History of QT prolongation, long QT syndrome, or torsade de pointes;
  • Subjects with a history of (excluding basal cell carcinoma) within 5 years before screening;
  • History of acute infection within 14 days prior to screening;
  • History of prescription drug abuse or illicit drug use within 6 months before screening, or drug abuse screening positive at baseline (D-1);
  • Consumption of more than 14 units of alcohol per week (1 unit of alcohol = 360 mL of beer or 45 mL of spirits containing 40% alcohol or 150 mL of wine) within 6 months before screening or consumption of alcoholic products 48 hours before dosing, or positive baseline (D-1) alcohol breath test; participation in strenuous exercise 48 hours before dosing;
  • Any prescription drugs, over-the-counter drugs, any vitamin products or herbal medicines that affect blood uric acid levels within 14 days prior to the first dose;
  • Moderate to severe smoker (more than 10 cigarettes per day) within 6 months prior to screening;
  • Subjects who have a history of special diet (eg, coffee and other caffeine-containing and alcoholic beverages, tea, grapefruit, etc.) within 14 days before screening;
  • Subjects who become diarrhea for drinking milk are excluded from the food effect group.
  • (HIV) antibody positive or syphilis (TP) antibody positive;
  • Women who have positive blood pregnancy (β-HCG) test at screening period or baseline (D-1) or are lactating or plan to have children from before the first dose to 3 months after the end of the trial;
  • Receiving any other study drug within 3 months prior to the first dose of study drug, or planning to use the study drug during the study;
  • History of blood donation or blood loss of more than 400 mL within 30 days prior to screening;
  • Any other conditions that, in the opinion of the investigator, might affect the subject's ability to give informed consent or to follow the protocol, or that the subject's participation in the trial might affect the trial's results or his/her own safety.

For MAD study

Inclusion Criteria:

  • Male or female Chinese subjects between 18 and 65 years of age, inclusive of the cutoff values, the time of signing the informed consent shall prevail;
  • Body mass index between 19 and 32 kg/m2 (including cutoff values) at screening;
  • Serum uric acid (sUA) ≥ 420 μmol/L (7.0 mg/dL) at screening or baseline (D-1);
  • Patients met 2015 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for gout at screening and without risk of acute gout attack;
  • Subjects do not use any uric acid-lowering drugs within 2 weeks prior to dosing;
  • Males and females of childbearing potential must agree to use at least one medically acceptable form of contraception (see Appendix for specific contraceptive measures) from screening through 3 months after the last dose;
  • The subject fully understands the purpose, nature, method and possible adverse reactions of the trial, voluntarily acts as a subject, and signs the informed consent form;
  • Able to complete trial per protocol requirements.

Exclusion Criteria:

  • Clinically abnormal diseases or factors, including but not limited to neurological, cardiovascular, hematological, hepatic, renal, gastrointestinal, respiratory, metabolic, endocrine, immunological, skeletal system diseases or other factors, which investigator considered inappropriate for study participation;
  • Patients with a history of gastrointestinal surgery or resection (subjects who have undergone appendectomy and/or herniorrhaphy may be included in the study);
  • Clinically significant liver function test abnormalities define as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 1.5 times of the upper limit of normal (ULN) or total bilirubin (TBIL) > ULN at screening or baseline (D-1); or history of clinically significant acute or chronic hepatitis (including infectious, metabolic, autoimmune, hereditary, ischemic, or other forms), liver cirrhosis, or liver tumor.
  • sCr > 132.6 μmol/L (1.5 mg/dL) and/or ≤ 60 mL/min/1.73 m2 (calculated by CKD-EPI formula) at screening;
  • Significant cardiovascular diseases, including:

    1. Acute decompensated heart failure, including exacerbation of chronic heart failure, manifests as signs and symptoms requiring hospitalization and/or intravenous diuretic therapy [New York Heart Association (NYHA) class III to IV], or hemodynamically significant valvular disease and/or other vascular obstructive lesions within 3 months prior to the screening visit;
    2. Any of the following within 6 months prior to the screening visit:

      • Significant cardiac, cerebral, and/or carotid artery diseases, including but not limited to acute coronary syndrome, myocardial infarction, stroke, and/or transient ischemic attack, or unsatisfactory recovery or unstable control at screening;
      • Major cardiovascular or percutaneous procedures, including cardiac ablation, coronary revascularization, and carotid angioplasty; cardiovascular disease likely to require surgical or percutaneous intervention during participation in the study or within 6 months of the screening visit;
    3. History of clinically significant cardiac arrhythmia, including but not limited to any of the following:

      • Symptomatic bradycardia and/or symptomatic ventricular arrhythmia within 3 months prior to the screening visit;
      • Second- or third-degree atrioventricular block, sick sinus syndrome, left bundle branch block;
      • New or untreated atrial fibrillation [Subjects with atrial fibrillation with stable (at least 6 months) asymptomatic heart rate control on appropriate therapy (which may include anticoagulation) are allowed to enroll in this study];
      • QTcF > 450 ms for males and > 470 ms for females prior to screening or randomization;
      • History of QT prolongation, long QT syndrome, or torsade de pointes;
      • History of cardiac transplantation, or subject on cardiac transplant checklist or use of left ventricular assist device;
  • History of prescription drug abuse or illicit drug use within 6 months before screening, or drug abuse screening positive at baseline (D-1);
  • Consumption of more than 14 units of alcohol per week (1 unit of alcohol = 360 mL of beer or 45 mL of spirits containing 40% alcohol or 150 mL of wine) within 6 months before screening or consumption of alcoholic products 48 hours before dosing, or positive baseline (D-1) alcohol breath test;
  • Any prescription drug, over-the-counter drug, any vitamin product, or herbal medicine that had an effect on serum uric acid level within 14 days prior to the first dose; exceptions can be discussed on a case-by-case basis (e.g., long-term stable use of low dose aspirin) after discussion and agreement between the investigator and the Sponsor;
  • Participates in strenuous exercise 48 hours before administration;
  • Human immunodeficiency virus (HIV) antibody positive or syphilis (TP) antibody positive;
  • Women who have positive pregnancy test or are lactating during the screening period or baseline (D-1) or plan to have children from before the first dose to 3 months after the end of the trial;
  • Patients who have received any other drugs within 3 months prior to the first dose of study drug or plan to use investigational drugs during the study;
  • History of blood donation or blood loss of more than 400 mL within 30 days prior to screening;
  • Patients with a history of malignancy (excluding basal cell carcinoma) within 5 years before screening;
  • History of acute infection within 14 days prior to screening;
  • Any other conditions that, in the opinion of the investigator, might affect the subject's ability to give informed consent or to follow the protocol, or that the subject's participation in the trial might affect the trial's results or his/her own safety.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    SAP-001

    Four sequentially ascending dose cohorts are set in SAD study. Three sequentially ascending dose cohorts are set in MAD study.

    Drug: SAP-001

  • Experimental
    Placebo

    placebo tablets for oral

    Drug: Placebo

  • Experimental
    A Randomized, Open-label, two-period crossover FE study

    12 subjects are randomized in a 1:1 ratio to sequences A (fasting - fed) and B (fed - fasting).

    Drug: SAP-001

Interventions

  • Solid Oral Tablet

    Also known as: SAP-001 tablet

  • DrugPlacebo

    Solid Oral Tablet

    Also known as: placebo tablet

06

What researchers measure

Primary outcomes

  1. maximum concentration (Cmax)

    PK parameters

    Time frame: 168 hours

  2. area under the drug concentration-time curve from time 0 to the last measurable concentration sample collection time t (AUC0-t)

    PK parameters

    Time frame: 168 hours

  3. area under the drug concentration-time curve from time 0 to 168 hours (AUC0-168h)

    PK parameters

    Time frame: 168 hours

  4. time to maximum concentration (Tmax)

    PK parameters

    Time frame: 168 hours

  5. elimination half-life (t1/2)

    PK parameters

    Time frame: 168 hours

  6. cumulative urinary excretion from 0 to 168 h (Ae0-168h)

    PK parameters

    Time frame: 168 hours

  7. cumulative urinary excretion rate, renal clearance (CLR168h)

    PK parameters

    Time frame: 168 hours

Secondary outcomes

  1. Serum uric acid area under curve (AUCUA)

    Pharmacodynamic Endpoints

    Time frame: 168 hours

  2. cumulative excretion of uric acid (AeUA)

    Pharmacodynamic Endpoints

    Time frame: 168 hours

  3. renal clearance (CLRUA)

    Pharmacodynamic Endpoints

    Time frame: 168 hours

  4. serum creatinine area under curve (AUCCr)

    Pharmacodynamic Endpoints

    Time frame: 168 hours

07

Study locations

1 site
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Dec 2023, 6 months.

Of 37 industry-sponsored phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 6 months is close to that.

Counting every sponsor, half of 41 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2023
First posted
Nov 7, 2024
StartActual
May 29, 2023
Primary completionActual
Dec 20, 2023
CompletionActual
Jan 11, 2024
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06678581
Lead sponsor
Shanton Pharma Co., Ltd.
Responsible party
Sponsor
First posted
Nov 7, 2024
Start date
May 29, 2023
Primary completion
Dec 20, 2023
Completion
Jan 11, 2024
Last update
Nov 12, 2024

Study contacts

Li Li
study director · Shanton Pharma Co., Ltd.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SAP-001

Start the discussion